| [1] |
Vranic S, Palazzo J, Sanati S，et al. Potential novel therapy targets in neuroendocrine carcinomas of the breast[J]．Clin Breast Cancer, 2019, 19(2): 131-136.
|
| [2] |
Feyrter F, Jartmann G. Uber die carcinoide wuchsform des carcinoma mammae, insbesondere das carcinoma solidum (gelatinosum) mammae [on the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (gelatinosum) mammae[J]．Frankf Z Pathol，1963, 73：24-39.
|
| [3] |
Böcker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics[J]．Verh Dtsch Ges Pathol, 2002, 86: 116-119.
|
| [4] |
Kawasaki T, Mochizuki K, Yamauchi H, et al. Neuroendocrine cells associated with neuroendocrine carcinoma of the breast: nature and significance[J]. J Clin Pathol, 2012, 65(8): 699-703.
|
| [5] |
Wachter DL, Hartmann A, Beckmann MW，et al. Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma[J]. Biomed Res Int, 2014, 2014: 408 459.
|
| [6] |
Kaur G, Mitra S, Singh G，et al. Neuroendocrine carcinoma of the breast arising in malignant phyllodes tumor[J]. Breast J, 2020, 26(2): 276-277.
|
| [7] |
Tan PH, Ellis I, Allison K，et al. The 2019 World Health Organization classification of tumours of the breast[J]. Histopathology, 2020，77(2)：181-185.
|
| [8] |
Frank GA, Danilova NV, Andreeva LL，et al. WHO classification of tumors of the breast, 2012[J]. Arkh Patol，2013，75(2)：53-63.
|
| [9] |
Marchiò C, Geyer FC, Ng CK，et al. The genetic landscape of breast carcinomas with neuroendocrine differentiation[J]．J Pathol, 2017, 241(3): 405-419.
|
| [10] |
Xiang DB, Wei B, Abraham SC，et al. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma[J]．Hum Pathol, 2014, 45(9): 1951-1956.
|
| [11] |
Ang D, Ballard M, Beadling C，et al. Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets[J]．Appl Immunohistochem Mol Morphol, 2015, 23(2): 97-103.
|
| [12] |
Weigelt B, Geyer FC, Horlings HM, et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type[J]．Mod Pathol, 2009, 22(11): 1401-1414.
|
| [13] |
王玺皓，蔡健，华平．伴神经内分泌特征的浸润性乳腺癌一例及文献复习[J/CD]．中华乳腺病杂志(电子版)，2018，12(4)：250-252.
|
| [14] |
程玉书，周正荣，杨文涛，等．乳腺神经内分泌癌的影像学表现和临床病理特征[J]．中华肿瘤杂志，2012，34(12)：917-922.
|
| [15] |
Günhan-Bilgen I, Zekioglu O, Ustün EE, et al. Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings[J]．Eur Radiol, 2003, 13(4): 788-793.
|
| [16] |
Yoon YS, Kim SY, Lee JH, et al. Primary neuroendocrine carcinoma of the breast: radiologic and pathologic correlation[J]．Clin Imaging, 2014, 38(5): 734-738.
|
| [17] |
Munoz-Zuluaga CA, Kotiah S, Studeman KD. High-grade poorly differentiated neuroendocrine carcinoma of the breast with low oncotype Dx recurrence score: a case report[J]. Breast Dis, 2017, 37(2): 99-103.
|
| [18] |
Bergstrom C, Porembka J, Fang Y, et al. Primary neuroendocrine carcinoma of the breast[J]．Breast J, 2019, 25(3): 519-520.
|
| [19] |
Roininen N, Takala S, Haapasaari KM, et al. Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study[J]．BMC Cancer, 2017, 17(1): 72.
|
| [20] |
Hejjane L, Oualla K, Bouchbika Z, et al. Primary neuroendocrine tumors of the breast: two case reports and review of the literature[J]．J Med Case Rep, 2020, 14(1): 41.
|
| [21] |
Kelten Talu C, Savli TC, Huq GE, et al. Histopathological and clinical differences between primary breast carcinomas with neuroendocrine features and primary breast carcinomas mimicking neuroendocrine features[J]．Int J Surg Pathol, 2019, 27(7): 744-752.
|
| [22] |
Lai BS, Tsang JY, Poon IK, et al. The clinical significance of neuroendocrine features in invasive breast carcinomas[J]. Oncologist, 2020, 25(9): e1318-e1329.
|
| [23] |
Cheymol C, Abramovici O, Do Cao C, et al. Tumeurs neuroendocrines primitives du sein: mythe ou réalité ? Une revue de la littérature [Neuroendocrine tumors of the breast: Myth or reality? A systematic review][J]. Bull Cancer，2018，105(4)：431-439.
|
| [24] |
Irelli A, Sirufo MM, Morelli L, et al. Neuroendocrine cancer of the breast: a rare entity[J]．J Clin Med, 2020，9(5)：1452.
|
| [25] |
华彬，张伟，陆旭，等．乳腺原发神经内分泌癌的临床病理特点分析[J]. 中国医刊，2018, 53(5)：522-527.
|
| [26] |
Inno A, Bogina G, Turazza M, et al. Neuroendocrine carcinoma of the breast: current evidence and future perspectives[J]. Oncologist, 2016, 21(1)：28.
|
| [27] |
Terlević R, Perić Balja M, Tomas D, et al. Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer[J]. Ann Diagn Pathol，2019，38：62-66.
|
| [28] |
Lavigne M, Menet E, Tille JC, et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast[J]. Mod Pathol, 2018，31(1)：68-82.
|
| [29] |
Vranic S, Palazzo J, Sanati S, et al. Potential novel therapy targets in neuroendocrine carcinomas of the breast[J]. Clin Breast Cancer，2019，19(2)：131-136.
|
| [30] |
Signore A, Lauri C, Auletta S, et al. Radiopharmaceuticals for breast cancer and neuroendocrine tumors: two examples of how tissue characterization may influence the choice of therapy[J]. Cancers (Basel)，2020，12(4)：781.
|
| [31] |
Velikyan I. (Radio)Theranostic patient management in oncology exemplified by neuroendocrine neoplasms, prostate cancer, and breast cancer[J]. Pharmaceuticals (Basel), 2020，13(3)：39.
|
| [32] |
Liu YH, Tsang JY, Ni YB, et al. Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation[J]. Oncotarget, 2016, 7(2): 1464-1476.
|